Top-Rated StocksTop-RatedNASDAQ:STTK Shattuck Labs (STTK) Stock Price, News & Analysis $5.86 -0.64 (-9.85%) Closing price 04:00 PM EasternExtended Trading$5.86 0.00 (-0.09%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Shattuck Labs Stock (NASDAQ:STTK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Shattuck Labs alerts:Sign Up Key Stats Today's Range$5.85▼$6.6550-Day Range$5.85▼$8.0652-Week Range$1.70▼$8.33Volume1.60 million shsAverage Volume1.56 million shsMarket Capitalization$588.11 millionP/E RatioN/ADividend YieldN/APrice Target$13.33Consensus RatingBuy Company Overview Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to create biologic medicines that combine immune checkpoint blockade with immune-cell activation in a single therapeutic construct. Shattuck’s pipeline has included investigational ARC fusion proteins intended to alter the tumor microenvironment and stimulate immune responses against cancer cells. Its lead programs have been evaluated in clinical studies involving advanced solid tumors and hematologic malignancies, including research into therapies targeting CD47 and CD40 ligand pathways. The company continues to assess applications of its platform across oncology and potentially other disease areas. Shattuck Labs was founded in 2016 and maintains operations in the United States. The company is led by Taylor Schreiber, M.D., Ph.D., who serves as president and chief executive officer. Its therapies remain investigational and are subject to clinical testing and regulatory review.AI Generated. May Contain Errors. Read More Shattuck Labs Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreSTTK MarketRank™: Shattuck Labs scored higher than 49% of companies evaluated by MarketBeat, and ranked 495th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingShattuck Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 9 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialShattuck Labs has a consensus price target of $13.33, representing about 127.5% upside from its current price of $5.86.Amount of Analyst CoverageShattuck Labs has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Shattuck Labs' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Shattuck Labs are expected to decrease in the coming year, from ($0.45) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Shattuck Labs is -11.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Shattuck Labs is -11.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioShattuck Labs has a P/B Ratio of 4.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Shattuck Labs' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.44% of the float of Shattuck Labs has been sold short.Short Interest Ratio / Days to CoverShattuck Labs has a short interest ratio ("days to cover") of 8.38.Change versus previous monthShort interest in Shattuck Labs has recently increased by 22.21%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldShattuck Labs does not currently pay a dividend.Dividend GrowthShattuck Labs does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.35 News SentimentShattuck Labs has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Shattuck Labs this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for STTK on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Shattuck Labs to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Shattuck Labs insiders have not sold or bought any company stock.Percentage Held by Insiders8.79% of the stock of Shattuck Labs is held by insiders.Percentage Held by Institutions58.74% of the stock of Shattuck Labs is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Shattuck Labs' insider trading history. Receive STTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shattuck Labs and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STTK Stock News HeadlinesShattuck Labs (STTK) Receives a Buy from Leerink PartnersOctober 5 at 7:31 PM | theglobeandmail.comNeedham & Company LLC Forecasts Strong Price Appreciation for Shattuck Labs (NASDAQ:STTK) StockOctober 4 at 1:36 AM | americanbankingnews.comYour book is insideStop one bad trade from turning into a bad week. The free report How To Stop Revenge Trading in 5 Steps lays out the exact rules used to break the cycle before it starts. It normally sells for $29.97, but it is currently available at no cost.October 6 at 1:00 AM | Profits Run (Ad)Financial Contrast: MDxHealth (NASDAQ:MDXH) and Shattuck Labs (NASDAQ:STTK)October 2, 2026 | americanbankingnews.comShattuck Labs Plans Phase 2 Trial of Chronic Inflammatory Skin Disease DrugOctober 1, 2026 | finance.yahoo.comShattuck Advances SL-325 Into Phase 2 Hidradenitis Suppurativa TrialOctober 1, 2026 | rttnews.comShattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical DevelopmentOctober 1, 2026 | globenewswire.comShattuck Labs, Inc. (NASDAQ:STTK) Stock Rated "Buy" by Sell-Side BrokeragesSeptember 30, 2026 | americanbankingnews.comSee More Headlines STTK Stock Analysis - Frequently Asked Questions How have STTK shares performed this year? Shattuck Labs' stock was trading at $3.65 at the beginning of the year. Since then, STTK stock has increased by 60.5% and is now trading at $5.86. How were Shattuck Labs' earnings last quarter? Shattuck Labs, Inc. (NASDAQ:STTK) released its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.00. When did Shattuck Labs IPO? Shattuck Labs (STTK) raised $178 million in an initial public offering on Friday, October 9th 2020. The company issued 11,882,352 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Evercore ISI acted as the underwriters for the IPO and Needham & Co. was co-manager. How do I buy shares of Shattuck Labs? Shares of STTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Shattuck Labs own? Based on aggregate information from My MarketBeat watchlists, some other companies that Shattuck Labs investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/11/2026Today10/06/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 STTK's financial health is in the Green zone, according to TradeSmith. STTK has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:STTK CIK1680367 Webwww.shattucklabs.com Phone512-900-4690FaxN/AEmployees40Year Founded2016Price Target and Rating Average Price Target for Shattuck Labs$13.33 High Price Target$19.00 Low Price Target$7.00 Potential Upside/Downside+127.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.81 million Net MarginsN/A Pretax Margin-5,256.80% Return on Equity-43.57% Return on Assets-40.90% Debt Debt-to-Equity RatioN/A Current Ratio27.59 Quick Ratio27.59 Sales & Book Value Annual Sales$1 million Price / Sales588.11 Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book4.51Miscellaneous Outstanding Shares100,360,000Free Float91,541,000Market Cap$588.11 million OptionableOptionable Beta1.09 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:STTK) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...Brownstone Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredParisian Penthouse: $650 a month (and your own chauffeur)A penthouse apartment for 650 a month in one of the ritziest neighborhoods in the city, comparable to Manhatta...International Living | SponsoredTrump Once Threatened THIS Country (Not Iran)Trump recently threatened a major economy not Iran, Canada, Mexico, or China over a new law that could hurt on...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shattuck Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shattuck Labs With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
